Results from similar experiments on EGFR (HER1-activated) breast cancer cells such as MDA-468 showed that the effect of drug treatment on EGR4-S levels within this context was still present but not as robust as that observed in HER2+ cell lines (Figure 5C). Here, ERBB2 is linked to breast carcinoma.